This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stambler, B. S. Articles by Laurita, K. R. Search for Related Content PubMed PubMed Citation Articles by Stambler, B. S. Articles by Laurita, K. R. Related Collections Arrhythmias, clinical electrophysiology, drugs Congestive Animal models of human disease Arrythmias-basic studies Calcium cycling/excitation-contraction coupling Heart failure - basic studies Related Article

Editorials

Atrial Fibrillation in Heart Failure

Steady Progress but Still a Long Way to Go

Bruce S. Stambler, MD and Kenneth R. Laurita, PhD

From the University Hospitals Case Medical Center (B.S.S.) and MetroHealth Campus (K.R.L.), Case Western Reserve University, Cleveland, Ohio.

Correspondence to Bruce Stambler, MD, 11100 Euclid Ave, Cleveland, OH 44106. E-mail bss4@cwru.edu

Key Words: atrial fibrillation • heart failure • calcium • atrium • electrophysiology

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Management of atrial tachyarrhythmias, especially atrial fibrillation (AF), in patients with congestive heart failure (CHF) remains a major challenge. It is widely recognized that CHF promotes AF and that AF worsens CHF. An individual with either condition who develops the other has higher morbidity and poorer prognosis. The prevalence of AF and CHF is expected to increase as the population ages. Therefore, it remains just as likely as it was more than a decade ago that the emerging epidemic of AF and CHF will continue to be both a challenge and an opportunity.

Article p 93

Current antiarrhythmic drugs (AADs) for AF prevention in patients with CHF remain unsatisfactory, with limited efficacy and considerable potential for adverse effects. Preliminary results from a large trial examining whether a rhythm-control strategy is superior to a rate-control strategy in patients with AF and CHF do not suggest a benefit in cardiovascular mortality rate, CHF, or stroke by attempting to maintain sinus rhythm with current AAD therapy (primarily amiodarone).¹ Newer nonpharmacological therapies, including pulmonary vein (PV) isolation and cardiac resynchronization therapy, are generating considerable interest; however, their rates of efficacy in patients with AF and CHF have not been established definitively. Thus, continued progress toward an enhanced understanding of upstream mechanisms that promote AF and contractile dysfunction in CHF and development of innovative therapeutic approaches based on fundamental, mechanistic insights is of paramount importance.

In this context, the study by Yeh et al² in this issue of Circulation: Arrhythmia and Electrophysiology provides important new . . . [Full Text of this Article]

Related Article

Calcium-Handling Abnormalities Underlying Atrial Arrhythmogenesis and Contractile Dysfunction in Dogs With Congestive Heart Failure

Yung-Hsin Yeh, Reza Wakili, Xiao-Yan Qi, Denis Chartier, Peter Boknik, Stefan Kääb, Ursula Ravens, Pierre Coutu, Dobromir Dobrev, and Stanley Nattel
Circ Arrhythm Electrophysiol 2008 1: 93-102. [Abstract] [Full Text] [PDF]